ClinicalTrials.gg
Not yet recruitingNCT07344987Updated Jan 15, 2026

Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

An interventional study of Air Purifier (with Filter) Arm and Purifier (without Filter) Arm in ILD, sponsored by Peking Union Medical College. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Peking Union Medical College · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.

02

Conditions studied

  • ILD
03

In context

Lead sponsor

Peking Union Medical College is the lead sponsor of 58 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with interstitial lung disease (ILD).
  • Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.

Exclusion criteria

Exclusion Criteria:

  • Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.
  • A history of respiratory tract infection within the past two weeks.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Sham comparator
    Purifier (without Filter) Arm

    Behavioral: Purifier (without Filter) Arm

  • Experimental
    Air Purifier (with Filter) Arm

    Behavioral: Air Purifier (with Filter) Arm

Interventions

  • BehavioralAir Purifier (with Filter) Arm

    Place an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day.

  • BehavioralPurifier (without Filter) Arm

    Place an air purifier without a filter in the home.

06

What researchers measure

Primary outcomes

  1. Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)

    St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient.

    Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

  2. Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)

    Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

  3. Quality of Life Indicators (e.g., CAT Score)

    COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient.

    Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

  4. Blood Sample Indicators (e.g., Concentration of Interleukin-8)

    Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8

    Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The informed consent form signed by study participants does not include clauses authorizing the sharing of de-identified individual participant data (IPD) with external researchers. In accordance with the ethical approval requirements, no secondary use of IPD beyond the primary study objectives is permitted without explicit participant consent. The sample size of this study is relatively small, and the collected IPD has high heterogeneity due to individual differences in patient clinical characteristics and intervention responsiveness. Sharing such a limited dataset may not support robust secondary research findings, and could lead to misleading interpretations of the intervention effect on pulmonary inflammation.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 15, 2026
StartEst.
Mar 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07344987
Lead sponsor
Peking Union Medical College
Responsible party
Hongbing Xu (Prof., Peking Union Medical College) — Principal investigator
First posted
Jan 15, 2026
Start date
Mar 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion